SHILPAMED Stock View

Shilpa Medicare Ltd
stock-view-header

₹ 348.6

icon 4.20 | 1.19
Market Cap ₹( Cr.)
30,506.53
Proj. P/E (x)
Proj. P/BV (x)
Proj. ROE (%)
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)

Stock View

Last Updated On.
17-Sep-2023
 

The average score for Shilpa Medicare Ltd stands at 1 against 1, three months back.

Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in research and development, manufacturing and sale of oncology drugs and formulations. Its products consist of oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. It supplies oncology APIs and intermediates. Its oncology/non-oncology APIs include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib HCL, and Irinotecan HCL Trihydrate for various regulated markets, including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. It is also engaged in manufacturing and sale of Lenvatinib Capsules under the brand name Lenshil.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
350.21
100 DMA(₹)
302.60
200 DMA(₹)
282.77
52 Weeks Range
222.40     399.05

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required